West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

Go back to West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
(NASDAQ: ICCM) Delayed: 2.23 +0.03 (1.36%)
Previous Close $2.20    52 Week High
Open $2.20    52 Week Low
Day High $2.25    P/E N/A 
Day Low $2.13    EPS
Volume 58,440